DPX Technologies Announces New Automated Workflows and Expanded Liquid Handler Compatibility for Genomic Testing
COLUMBIA, S.C., June 4, 2025 /PRNewswire/ -- DPX Technologies, a biotechnology company providing solutions for automated sample preparation, announces their latest products and fully automated workflows utilizing functionalized pipette tips. The products, MicroPorous Xtraction (MPX) Tips and NiXTips™, are designed for DNA extraction and nucleic acid clean up, respectively. Launched in 2024, NiXTips were first developed with compatibility on Hamilton® Robotics platforms and Agilent Bravo systems, but are now available for use on Integra VIAFLO semi-automated liquid handlers.
New automated workflows using 1 mL MPX Tips for DNA extraction and NiXTips for highly efficient size selection have been designed to resolve common challenges with current traditional methods. INTip methods simplify workflows by eliminating bead capture time, bead carryover, bead resuspension and requirements for magnets. Additionally, automated INTip methods utilize the robotic liquid handler to reduce hands-on processing time and reduce opportunities for sample contamination and experimental errors.
'We're thankful for the continued partnership with our customers that have brought MPX technology and NiXTips beyond the beta-testing phase,' Dr. William Brewer, Founder and CEO of DPX Technologies. 'With the launch of NiXTips and now MPX Tips, DPX can provide automated solutions to streamline genomic sample preparation.'
DPX Technologies offers custom method development and automation support to ensure an optimized workflow based on unique variables such as sample volume, DNA fragment size, buffer composition, binding cycles, etc.
Product Specifications
For more information on DPX's offering for genomic applications, please visit https://dpxtechnologies.com/genomics/.
About DPX Technologies
DPX Technologies is a leading provider of automated solutions for food safety testing, clinical laboratory testing, cannabis testing, forensic toxicology, genomics and proteomics sample preparation. DPX is committed to providing innovative sample purification solutions that increase efficiencies, unleashing the potential for scientists to solve problems with chemistry. We collaborate with our customers to provide the high-quality products they need for complex chemical and biological analysis.
View original content to download multimedia: https://www.prnewswire.com/news-releases/dpx-technologies-announces-new-automated-workflows-and-expanded-liquid-handler-compatibility-for-genomic-testing-302472355.html
SOURCE DPX Technologies
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme（the tradename of Merck & Co., Inc., Rahway, NJ, USA）is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy； OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy； OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Yahoo
5 hours ago
- Yahoo
Japanese AI Unicorn Notta Enters Otter AI's Market with Innovative Smart Voice Recorder
Notta Bets Big on AI Agent-Powered Voice Recorder as Hardware-SaaS Convergence Accelerates TOKYO, June 6, 2025 /PRNewswire/ -- As OpenAI's ChatGPT dominates enterprise AI adoption and Google Gemini reshapes how businesses think about AI assistants, Japanese unicorn Notta announced its ambitious push into the U.S. hardware market with the Notta Memo AI Voice Recorder. From Tokyo to Silicon Valley: The Underdog Story Notta's journey reads like a classic tech disruption playbook, albeit with a Japanese twist. Since launching in 2020, the company has quietly built a formidable AI transcription empire, amassing over 10 million users globally and signing up 4,000 enterprise customers. The real validation? A staggering 68% of Japan's Nikkei 225 companies—the country's most elite corporations—have integrated Notta's AI solutions into their workflows. "Most observers underestimate just how competitive the Japanese enterprise market is," explains industry analyst Sarah from TechInsight Research. "If you can win over two-thirds of the Nikkei 225, you've proven enterprise-grade reliability at scale." Notta's 2022 Airgram acquisition was just the opening move—the company believes the real opportunity lies in completely reimagining how voice technology integrates into daily workflows. Security-First Approach Gives Notta Enterprise Edge Unlike many AI startups that retrofit compliance as an afterthought, Notta built enterprise security into its foundation from day one. The company holds ISO/IEC 27001 and SOC 2 Type II certifications—credentials that remain elusive for many competitors still scrambling to meet Fortune 500 requirements. More critically, Notta has secured the regulatory trifecta that unlocks major markets: GDPR compliance for European expansion, HIPAA certification for healthcare disruption, and CCPA adherence for California's privacy-conscious landscape. This compliance-first strategy positions Notta to compete for high-value enterprise contracts that security-conscious organizations won't trust to less mature platforms. Hardware Meets AI: The Five-Platform Ecosystem Play The Notta Memo distinguishes itself in the crowded voice recording market through its unique five-platform ecosystem integration—seamlessly connecting web, iOS, Android, Chrome extension, and the Memo device itself. This comprehensive approach addresses the fragmented user experience that has long plagued the industry. Unlike traditional voice recording solutions that force users to choose between SaaS flexibility and hardware reliability, Notta Memo delivers both. The device features advanced bone-conduction technology for complete phone call recording, intelligent noise reduction for crystal-clear audio capture, and one-tap synchronization with Notta. "We're not just launching another recording device," said Ryan, CEO of Notta. "We're introducing a complete AI-powered voice ecosystem that adapts to how people work and communicate in today's hybrid world. Our hardware becomes an extension of our proven AI platform that has already transformed millions of meetings worldwide." Beyond recording, Notta Memo is your AI-powered agent and centralized knowledge hub—seamlessly integrated across all your workflows. Competitive Positioning in a Dynamic Market Notta enters the US AI transcription market with an integrated approach that combines software and hardware innovation. While the market includes established players like Otter AI in the SaaS space and Plaud AI in hardware solutions, Notta differentiates itself through its comprehensive platform that leverages AI capabilities refined through years of serving millions of global users. The company acknowledges the challenges in competing against established players with loyal American user bases. However, Notta's proven track record of rapid user acquisition and revenue growth in Japan, combined with its technological differentiation, positions it as a formidable new entrant. Market Timing and Strategic Vision Notta's American expansion comes at a pivotal moment in the AI industry. As enterprises increasingly adopt AI agents for productivity enhancement and consumers demand more intelligent, seamless technology experiences, the convergence of AI SaaS and purpose-built hardware represents a natural evolution. The Notta Memo's launch signals more than just product diversification – it represents Notta's vision of AI-native hardware that thinks, learns, and adapts to user needs. This positions the company at the forefront of the next wave of AI innovation, where the distinction between SaaS and hardware dissolves into unified, intelligent experiences. About Notta Notta is the AI unicorn that's redefining how the world captures and understands conversations. Seamlessly integrating advanced SaaS with intelligent hardware, Notta turns conversations from any meeting, call, or discussion into actionable insights. This AI-powered, end-to-end solution captures and structures spoken interactions, creating a centralized knowledge hub. Media Contact: contact@ View original content to download multimedia: SOURCE Notta
Yahoo
5 hours ago
- Yahoo
Zero Gravity Lifts off on Documentary Showcase
LOS ANGELES, June 6, 2025 /PRNewswire/ -- Scientology Network's DOCUMENTARY SHOWCASE, the weekly series providing a platform for Independent filmmakers to air films on important social, cultural and environmental issues, presents the celestial documentary Zero Gravity on June 6, 2025. DOCUMENTARY SHOWCASE airs Fridays at 8 p.m. ET/PT on Scientology Network. In Zero Gravity, middle school students from San Jose, California, enter a nationwide NASA tournament to code satellites aboard the International Space Station (ISS). Led by an inspiring first-time coach, the team rises from budding digital dreamers to ultimately represent California in the ISS finals tournament—where astronauts execute the young coders' algorithms in orbit, 250 miles above Earth. Directed by Thomas Verrette, the film follows the kids' transformation and serves as a powerful reminder: the future begins with those bold enough to imagine it. An official selection at over 70 film festivals—including DOC NYC, Cinequest and the Cleveland International Film Festival—Zero Gravity has won 18 documentary awards from Audience Choice to Best Editing. Endorsed by scientists and educators, the film has reached more than 10,000 students nationwide through classroom and community screenings. ABOUT THOMAS VERRETTE Thomas Verrette is an award-winning director, producer and editor. A more than 15-year veteran of the film industry, Verrette is a former FOX and Disney creative and post-production executive. He is most known for producing the 20-episode World Cup docu-series Phenoms for FOX Sports. Verrette began his career upon graduating from the Savannah College of Art and Design. Zero Gravity is his first feature documentary as a director. ABOUT DOCUMENTARY SHOWCASE Fundamental to Scientology is a humanitarian mission that extends to some 200 nations with programs for human rights, human decency, literacy, morality, drug prevention and disaster relief. For this reason, the Scientology Network provides a platform for Independent filmmakers who embrace a vision of building a better world. DOCUMENTARY SHOWCASE debuts films weekly from award-winning Independent filmmakers whose goal is to improve society by raising awareness of social, cultural and environmental issues. For more information, visit Scientology Network debuted on March 12, 2018, launched by David Miscavige, ecclesiastical leader of the Scientology religion. Since then, Scientology Network has been viewed in over 240 countries and territories worldwide in 17 languages. Satisfying the curiosity of people about Scientology, the network takes viewers across six continents, spotlighting the everyday lives of Scientologists, showing the Church as a global organization and presenting its Social Betterment programs that have touched the lives of millions worldwide. The network also showcases documentaries by Independent filmmakers who represent a cross section of cultures and faiths, but share a common purpose of uplifting communities. Scientology Network's innovative content has been recognized with more than 125 industry awards, including Tellys, Communitas and Hermes Creative Awards. Broadcast from Scientology Media Productions, the Church's global media center in Los Angeles, Scientology Network is available on DIRECTV Channel 320, DIRECTV STREAM and AT&T U-verse and can be streamed at on mobile apps and via the Roku, Amazon Fire and Apple TV platforms. View original content to download multimedia: SOURCE Church of Scientology International
